Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study

Li, Hui-Zhou; Tan, Jie; Tang, Tian; An, Tian-Zhi; Li, Junxiang; Xiao, Yue

doi:10.2147/jhc.s338456

Cited by 8 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al. 20 reported that MWA and TACE using oil-epirubicin emulsion could provide a survival benefit in patients with hepatocellular carcinoma beyond the Milan criteria. The median progression-free survival and overall survival were 317 days and 1488 days, respectively.…”

Section: Discussionmentioning

confidence: 99%

Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers

Shi

Zhang

et al. 2023

Journal of Interventional Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers

Shi

Zhang

et al. 2023

Journal of Interventional Medicine

View full text Add to dashboard Cite

“…More recently, a retrospective study of patients with unresectable HCC stated that those treated with TACE followed by MWA had an OS and PFS of 49.6 months and 12.6 months, respectively, compared to an OS and PFS of 23.3 months and 8.2 months, respectively, in TACE only patients. 93 The downstaging to transplant rate was higher in the TACE plus MWA group as well. However, given that the patients were not strictly BCLC stage B, additional forthcoming studies with MWA will prove insightful in the patient population that can benefit most from this dual therapy.…”

Section: Looking Ahead On Future Practicementioning

confidence: 91%

Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines

Goyal

Salem

Mouli

2022

The British Journal of Radiology

View full text Add to dashboard Cite

Hepatocellular carcinoma is a leading cause of cancer-related deaths globally. Liver transplant remains the goal of curative treatment, but limited supply of organs decreases accessibility and prolongs waiting time to transplantation. Therefore, interventional oncology therapies have been used to treat the majority of HCC patients, including those awaiting transplant. The Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system in management of hepatocellular carcinoma (HCC) that helps allocate treatments. Since its inception in 1999 it was updated for the fifth time in November 2021 and for the first time shaped by expert opinions outside the core BCLC group. The most recent version includes additional options for early-stage disease, sub stratifies intermediate disease into three groups, and lists alternates to Sorafenib that can double the expected survival of advanced-stage disease. The group also proposed a new BCLC staging schema for disease progression, and endorsed treatment stage migration directly into the main staging and treatment algorithm. This article reviews the recent developments underlying the current BCLC guidelines, and highlights ongoing research, particularly involving radioembolization, that will shape future best practice.

show abstract

“…After PSM, MWA plus TACE yielded superior PFS and OS to TACE alone for BCLC stage B HCC [42,43]. Notably, the morphological criteria and treatment modality varied The above studies adopted a sequential treatment of MWA after TACE at an interval of at least one month, another study proposed a concurrent treatment of TACE and MWA [44].…”

Section: Ablationmentioning

confidence: 99%

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Xie¹,

Shi²,

Zhou³

et al. 2023

Clin Mol Hepatol

View full text Add to dashboard Cite

Liver cancer ranks the fourth most prevalent and the second most lethal cancer in China.Hepatitis B virus (HBV) infection represents the major risk factor for hepatocellular carcinoma(HCC) in China. Liver US plus AFP every 6 months continues to be the predominant surveillance modality. The aMAP score is newly recommended in the 2022 Chinese guidelines to predict HCC occurrence. China liver cancer (CNLC) staging system proposed in the 2017 guideline continues to be the standard model for staging with modifications in the treatment allocations. Considering the aggressive nature of HBV-associated HCC, multi-modal and high-intensity strategies treatments like the addition of immunotherapy-based systemic treatment to local therapies including resection, ablation, intra-arterial therapies have been adopted in real-life practices in China. The latest Chinese guidelines recommend atezolizumab plus bevacizumab, suntilimab plus bevacizumab analogue, lenvatinib, sorafenib, donafenib and FOLFOX chemotherapy as the first-line treatment without priority. Apart from regorafenib, apatinib, camrelizumab and tislelizumab are newly added as the secondline systemic therapies for patients who progressed on sorafenib. Systemic therapies adopted in real life practice are sophisticated with various combination modality and different sequences.

show abstract

Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study

Cited by 8 publications

References 38 publications

Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers

Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers

Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Contact Info

Product

Resources

About